Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients (VEGA)
A Randomized, Double-masked, and Controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravitreal Administration of Aflibercept in Japanese Patients With Neovascular Glaucoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Gifu, Japan, 501-1194
-
Kyoto, Japan, 602-0841
-
Osaka, Japan, 545-8586
-
-
Fukui
-
Yoshida, Fukui, Japan, 910-1193
-
-
Hyogo
-
Amagasaki, Hyogo, Japan, 660-8550
-
Himeji, Hyogo, Japan, 671-1227
-
Kobe, Hyogo, Japan, 650-0017
-
-
Ishikawa
-
Kanazawa, Ishikawa, Japan, 920-8641
-
-
Kanagawa
-
Kawasaki, Kanagawa, Japan, 216-8511
-
-
Miyagi
-
Sendai, Miyagi, Japan, 980-8574
-
-
Oita
-
Yufu, Oita, Japan, 879-5593
-
-
Osaka
-
Hirakata, Osaka, Japan, 573-1191
-
Suita, Osaka, Japan, 565-0871
-
Takatsuki, Osaka, Japan, 569-8686
-
-
Shimane
-
Izumo, Shimane, Japan, 693-8501
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japan, 113-8655
-
Mitaka, Tokyo, Japan, 181-8611
-
-
Yamaguchi
-
Ube, Yamaguchi, Japan, 755-8505
-
-
Yamanashi
-
Chuo, Yamanashi, Japan, 409-3898
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Japanese men and women aged 20 years or older,
- Patients diagnosed as having Neovascular glaucoma (NVG) with neovascularization in the anterior segment (both iris and anterior chamber angle),
- Patients with Intraocular pressure (IOP) higher than 25 mmHg in the study eye due to anterior segment (both iris and anterior chamber angle) neovascularization.
Exclusion Criteria:
- Patients with angle-closure due to conditions other than Neovascular glaucoma
- Patients with a known or suspected ocular or peri-ocular infection,
- Patients with severe intraocular inflammation in the study eye,
- Women who are pregnant, suspected of being pregnant or lactating,
- Patients with known allergy to aflibercept.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Aflibercept
Aflibercept 2 mg Intravitreal (IVT) injection group
|
After the first aflibercept IVT injection on Day 1, subjects may receive sham injection at Week 1, and aflibercept injection at Week 5 and/or Week 9 if the re-treatment criteria are met.
|
|
Sham Comparator: Sham Injection
Sham injection group
|
After the first sham injection on Day 1, subjects may receive aflibercept IVT injection at Week 1, Week 5 and/or Week 9 if re-treatment criteria are met.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Intraocular Pressure (IOP) From Baseline to Pre-dose at Week 1
Time Frame: From baseline to pre-dose at Week 1
|
It compared the change in IOP from baseline to pre-dose at Week 1 between the aflibercept group vs the sham group.
|
From baseline to pre-dose at Week 1
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Subjects Who Had Improved Neovascularization of the Iris (NVI) Grade From Baseline to Pre-dose at Week 1
Time Frame: From baseline to pre-dose at Week 1
|
NVI were assessed in the study eye using the NVI grading systems (grade 0 to grade 4).
A subject who shows the improvement by at least one grade is considered to be improved.
Percentage of subjects who had improved NVI grade was reported.
|
From baseline to pre-dose at Week 1
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 17584
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.